Panel Discussion: Investigating Various Isotope Half-Lives as a Limiting Factor in Radiotherapeutic Scalability, Quality Control & Patient Access
- Defining how isotope half-life constrains manufacturing timelines, QC strategy, and logistics
- Contrasting mature distribution models for lutetium-177 with emerging requirements for short-lived isotopes such as astatine-211
- Identifying which capabilities in licensing, training, automation, and packaging can be leveraged across isotope classes